Summary
Synergy Pharmaceuticals Inc (Synergy Pharma), a subsidiary of Pawfect Foods Inc, develops therapies for gastrointestinal (GI) diseases using its proprietary GI platform, which is based on uroguanylin, a naturally occurring human GI peptide that promotes normal bowel function. The company concentrates in therapeutic areas such as chronic idiopathic constipation (CIC), opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C) and ulcerative colitis (UC). Synergy Pharma’s product portfolio includes plecanatide (SP-304), a drug candidate, which is used to treat CIC and IBS-C; and dolcanatide (SP-333) for the treatment of OIC and UC. The company develops product based on the natural human hormone. It has a research center in Philadelphia. Synergy Pharma is headquartered in New York, the US.
Synergy Pharmaceuticals Inc (SGYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Synergy Pharma Acquires FV-100 From Bristol-Myers Squibb 11
Partnerships 13
Bind Therapeutics and Synergy Pharma Enter into Research Agreement 13
Licensing Agreements 14
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 14
Equity Offering 15
Synergy Pharma Plans to Raise Funds in Public Offering of Shares 15
Synergy Pharma Raises USD89.8 Million in Private Placement of Shares 16
Synergy Pharma Announces Public Offering Of Shares For Up To US$50 Million 18
Synergy Pharma Completes Public Offering Of Shares For US$90 Million 19
Synergy Pharma Completes Exercise Of Underwriters' Option For Public Offering Of Shares For US$51.75 Million 21
Synergy Pharma Completes Exercise Of Over-Allotment Option For Public Offering Of Units For US$17.25 Million 23
Synergy Pharma Files Registration Statement For Public Offering Of Units For US$0.5 Million 25
Synergy Pharma Completes Private Placement Of Common Stock For US$5.7 Million 26
Synergy Pharma Files Registration Statement For Public Offering Of US$2.5 Million 27
Synergy Pharma Completes Private Placement Of US$0.4 Million 29
Synergy Pharma Completes Private Placement Of US$3 Million 30
Debt Offering 32
Synergy Pharma Raises USD200 Million in Private Placement of 7.5% Notes Due 2019 32
Acquisition 34
Synergy Pharma May Sell Itself 34
Synergy Pharma Completes Acquisition Of Callisto Pharma 35
Synergy Pharmaceuticals Inc - Key Competitors 37
Key Employees 38
Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List of Tables
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Synergy Pharmaceuticals Inc, Deals By Therapy Area, 2010 to YTD 2016 8
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Synergy Pharma Acquires FV-100 From Bristol-Myers Squibb 11
Bind Therapeutics and Synergy Pharma Enter into Research Agreement 13
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 14
Synergy Pharma Plans to Raise Funds in Public Offering of Shares 15
Synergy Pharma Raises USD89.8 Million in Private Placement of Shares 16
Synergy Pharma Announces Public Offering Of Shares For Up To US$50 Million 18
Synergy Pharma Completes Public Offering Of Shares For US$90 Million 19
Synergy Pharma Completes Exercise Of Underwriters' Option For Public Offering Of Shares For US$51.75 Million 21
Synergy Pharma Completes Exercise Of Over-Allotment Option For Public Offering Of Units For US$17.25 Million 23
Synergy Pharma Files Registration Statement For Public Offering Of Units For US$0.5 Million 25
Synergy Pharma Completes Private Placement Of Common Stock For US$5.7 Million 26
Synergy Pharma Files Registration Statement For Public Offering Of US$2.5 Million 27
Synergy Pharma Completes Private Placement Of US$0.4 Million 29
Synergy Pharma Completes Private Placement Of US$3 Million 30
Synergy Pharma Raises USD200 Million in Private Placement of 7.5% Notes Due 2019 32
Synergy Pharma May Sell Itself 34
Synergy Pharma Completes Acquisition Of Callisto Pharma 35
Synergy Pharmaceuticals Inc, Key Competitors 37
Synergy Pharmaceuticals Inc, Key Employees 38
Synergy Pharmaceuticals Inc, Subsidiaries 39
List of Figures
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
